An Open-Label, Three-Period, Fixed Sequence Study to Investigate the Effect of Multiple Oral Doses of Rifampin, a Potent Cytochrome P450 3A Inducer, on the Single Dose Pharmacokinetics of RO5424802 in Healthy Subjects

Trial Profile

An Open-Label, Three-Period, Fixed Sequence Study to Investigate the Effect of Multiple Oral Doses of Rifampin, a Potent Cytochrome P450 3A Inducer, on the Single Dose Pharmacokinetics of RO5424802 in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Dec 2016

At a glance

  • Drugs Alectinib (Primary) ; Rifampicin
  • Indications Non-small cell lung cancer
  • Focus Pharmacokinetics
  • Sponsors Roche
  • Most Recent Events

    • 12 Mar 2016 Results from this trial and other two trial (270330, 238878) presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 20 Jan 2014 According to ClinicalTrials.gov record study status changed to completed.
    • 04 Oct 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top